Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

周四，Wolfe Research调整了对Edwards Lifesciences (NYSE:EW)股票的看法，将其评级从"与同行持平"下调至"跑输大盘"。该公司还为这家医疗技术公司的股票设定了$60.00的目标价，目前该股交易价格为$70.28。

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

RBC Capital Markets对2025年医疗用品和设备板块的前景持乐观态度，认为Edwards Lifesciences等股票存在显著上涨机会。该公司的调查显示，公司在经导管瓣膜治疗方面存在潜在的市场增长。美银证券将Edwards ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Edwards Lifesciences stock fell Friday after the company said its all-important TAVR segment will face numerous — but one-time — challenges in the fourth quarter. Please watch the video at ...

The TAVR market has experienced a slowdown, with Edwards reducing its 2024 and second half of the year worldwide TAVR outlook to 5-7% year-over-year, down from the previously anticipated 8-10% growth.

TPL and TSM were top performers, while CDW and UnitedHealth were notable detractors for both the quarter and the year. Click ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies, has recently faced challenges in its core ...

Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral ...